Substituent Effects on Desferrithiocin and Desferrithiocin Analogue Iron-Clearing and Toxicity Profiles

被引:11
作者
Bergeron, Raymond J. [1 ]
Wiegand, Jan [1 ]
Bharti, Neelam [1 ]
McManis, James S. [1 ]
机构
[1] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA
基金
美国国家卫生研究院;
关键词
KIDNEY INJURY MOLECULE-1; CHELATION-THERAPY; DESAZADESFERRITHIOCIN ANALOGS; COORDINATION CHEMISTRY; OXIDATIVE DAMAGE; OVERLOAD; DEFERIPRONE; THALASSEMIA; BIOMARKER; ICL670;
D O I
10.1021/jm300509y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Desferrithiocin (DFT, 1) is a very efficient iron chelator when given orally. However, it is severely nephrotoxic. Structure-activity studies with 1 demonstrated that removal of the aromatic nitrogen to provide desazadesferrithiocin (DADFT, 2) and introduction of either a hydroxyl group or a polyether fragment onto the aromatic ring resulted in orally active iron chelators that were much less toxic than 1. The purpose of the current study was to determine if a comparable reduction in renal toxicity could be achieved by performing the same structural manipulations on 1 itself. Accordingly, three DFT analogues were synthesized. The iron-clearing efficiency and ferrokinetics were evaluated in rats and primates; toxicity assessments were carried out in rodents. The resulting DFT ligands demonstrated a reduction in toxicity that was equivalent to that of the DADFT analogues and presented with excellent iron-clearing properties.
引用
收藏
页码:7090 / 7103
页数:14
相关论文
共 73 条
[51]   Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia:: a randomised, double-blind, placebo-controlled, dose-escalation trial [J].
Nisbet-Brown, E ;
Olivieri, NF ;
Giardina, PJ ;
Grady, RW ;
Neufeld, EJ ;
Séchaud, R ;
Krebs-Brown, AJ ;
Anderson, JR ;
Alberti, D ;
Sizer, KC ;
Nathan, DG .
LANCET, 2003, 361 (9369) :1597-1602
[52]  
*NOV PHARM CORP, 2008, DESF
[53]   Iron-chelating therapy and the treatment of thalassemia [J].
Olivieri, NF ;
Brittenham, GM .
BLOOD, 1997, 89 (03) :739-761
[54]  
Olivieri NF, 1996, ACTA HAEMATOL-BASEL, V95, P37
[55]   Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major [J].
Olivieri, NF ;
Brittenham, GM ;
McLaren, CE ;
Templeton, DM ;
Cameron, RG ;
McClelland, RA ;
Burt, AD ;
Fleming, KA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07) :417-423
[56]   Progression of iron overload in sickle cell disease [J].
Olivieri, NF .
SEMINARS IN HEMATOLOGY, 2001, 38 (01) :57-62
[57]   An efficient synthesis of highly functionalized chiral lactams [J].
Ornelas, Martha A. ;
Gonzalez, Javier ;
Sach, Neal W. ;
Richardson, Paul F. ;
Bunker, Kevin D. ;
Linton, Angelica ;
Kephart, Susan E. ;
Pairish, Mason ;
Guo, Chuangxing .
TETRAHEDRON LETTERS, 2011, 52 (37) :4760-4763
[58]   Iron chelation beyond transfusion iron overload [J].
Pietrangelo, Antonello .
AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (12) :1142-1146
[59]  
Pippard M J, 1989, Baillieres Clin Haematol, V2, P323, DOI 10.1016/S0950-3536(89)80020-4
[60]   IRON OVERLOAD AND IRON CHELATION-THERAPY IN THALASSEMIA AND SICKLE-CELL HEMOGLOBINOPATHIES [J].
PIPPARD, MJ .
ACTA HAEMATOLOGICA, 1987, 78 (2-3) :206-211